LUCAR-G79D T cells for lupus and inflammatory muscle disease that returned
Tests LUCAR-G79D T cells in adults with returning lupus or muscle inflammation.
Plain-language title generated from the registry record
Registry title: A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
Key facts
- Where
- Bengbu, Changsha, Guangzhou, Nanchang, and Xuzhou, ChinaSee the 5 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07331272, who can take part
Where in China
- The Third The People's Hospital Of BengbuBengbu, ChinaTaking people
- Xiangya Hospital of Central South UniversityChangsha, ChinaNot yet recruiting
- Nanfang HospitalGuangzhou, ChinaNot yet recruiting
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaNot yet recruiting
- The affiliated hospital of xuzhou medical universityXuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanjing Legend Biotech Co.
- Trial code
- NCT07331272
- Record updated
- 2 February 2026
- Original description
This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.Read full original descriptionShow less
An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.
Inclusion: Subjects voluntary agreement to provide written informed consent; Aged 18 to 70 years, either sex; Adequate organ function meet screening criteria; Positive test for cluster of differentiation antigen 19 (CD19); SLE:; Have been diagnosed of SLE at least 6 months before screening; At screening, antinuclear antibody, and/or anti-dsDNA antibody, and/or anti-Smith antibody should be positive; Fulfill relapsed/refractory SLE conditions; IIM:; Have been diagnosed of IIM before screening; Positive test for myositis-associated antibodies or myositis-specific antibodies at screening; Fulfill relapsed/refractory IIM conditions.
Exclusion: Active infections such as hepatitis and tuberculosis; Other autoimmune diseases; Serious underlying diseases such as tumor, uncontrolled diabetes; Those with a history of major organ transplantation; Female subjects who were pregnant, breastfeeding.